Ibrutinib antagonizes rituximab-dependent NK cell–mediated cytotoxicity
Holbrook E K Kohrt, Idit Sagiv-Barfi, Sarwish Rafiq et al. · Blood · 2014
To the editor: Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) with promising activity in CD20+ B-cell malignancies including recent US Food and Drug Administration approval in mantle cell lymphoma.[1][1] Given the homology between BTK and interleukin-2 inducible tyrosine
Cited by 217 works. doi:10.1182/blood-2014-01-547869
Authors
- Holbrook E K Kohrt
- Idit Sagiv-Barfi
- Sarwish Rafiq
- Sarah E. M. Herman
- Jonathan P. Butchar
- Carolyn M. Cheney
- Xiaoli Zhang
- Joseph J. Buggy
- Natarajan Muthusamy
- Ronald Levy
- Amy Jo Johnson
- John C. Byrd
References
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- From the bench to the bedside: ways to improve rituximab efficacy
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- Specific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- Differential Regulation of Human NK Cell-Mediated Cytotoxicity by the Tyrosine Kinase Itk